Physician profile
Christopher A Grantham
NPI 1952484149
$8,039.90
in general payments reported to CMS, 2019-2025
20 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,202 · 2020: $583 · 2021: $538 · 2022: $958 · 2023: $1,262 · 2024: $974 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,550.35 | 2019-2020 | |
| Medtronic, INC. | $1,913.42 | 2021-2025 | Onyx Frontier, Symplicity G3, Ffrangio |
| Abbott Laboratories | $821.14 | 2019-2024 | Perclose Prostyle |
| Janssen Pharmaceuticals, INC | $773.48 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $640.68 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Novo Nordisk INC | $372.49 | 2022-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.39 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $143.92 | 2022-2025 | Eliquis |
| Portola Pharmaceuticals, LLC | $126.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $84.76 | 2022-2023 | Andexxa, Brilinta |
| Ge Healthcare | $74.33 | 2024 | |
| Amgen INC. | $53.08 | 2019 | |
| Scpharmaceuticals INC. | $52.37 | 2024 | |
| Medtronic Vascular, INC. | $35.21 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.12 | 2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $28.86 | 2023 | |
| Merck Sharp & Dohme LLC | $23.44 | 2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $21.88 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $19.10 | 2024 | |
| Chiesi USA, INC. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Grantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.